NCT04813705 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
| NCT ID | NCT04813705 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Taizhou Hospital |
| Condition | Nasopharyngeal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 93 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2024-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 93 participants in total. It began in 2022-01-01 with a primary completion date of 2024-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
Eligibility Criteria
Inclusion Criteria: 1. Pathology confirmed nasopharyngeal squamous cell carcinoma. 2. Stage I-IVA（8thAJCC/UICC staging system). 3. Aged 18-80 years. 4. KPS≥70. 5. Have measurable lesions on 18F-FDG PET/CT before treatment. 6. HGB≥90 g/L，ANC≥1.5×109 /L，PLT≥80×109 /L. 7. ALT,AST\<2.5 fold of ULN；TBIL\<2.0×ULN. 8. CCR≥60ml/min or Cr\<1.5×ULN. 9. Signed informed consent. 10. Have follow up condition. Exclusion Criteria: 1. Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ). 2. Age \<18 or \>80years. 3. Pregnancy or lactation. 4. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume). 5. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 6. With sever infection and internal disease. 7. Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.
Contact & Investigator
Haihua Yang, MD
PRINCIPAL INVESTIGATOR
Taizhou Enze Medical Center Group
Frequently Asked Questions
Who can join the NCT04813705 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04813705 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT04813705 currently recruiting?
Yes, NCT04813705 is actively recruiting participants. Contact the research team at yhh93181@hotmail.com for enrollment information.
Where is the NCT04813705 trial being conducted?
This trial is being conducted at Taizhou, China, Taizhou, China, Taizhou, China, Taizhou, China.
Who is sponsoring the NCT04813705 clinical trial?
NCT04813705 is sponsored by Taizhou Hospital. The principal investigator is Haihua Yang, MD at Taizhou Enze Medical Center Group. The trial plans to enroll 93 participants.